



ASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level

Tatsuaki Sumiyoshi, MD, and Kenichiro Uemura, MD

Department of Surgery of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan

PAST

Patients with pancreatic ductal adenocarcinoma (PDAC) with a Lewis antigen-negative phenotype secrete very little or no carbohydrate antigen (CA) 19-9. Therefore, PDAC patients with normal CA 19-9 levels can have early-stage cancer or advanced cancer without elevation of CA19-9 level; thus, estimating their malignant potential is difficult.

PRESENT

The combined use of CA19-9 and Duke pancreatic monoclonal antigen type 2 (DUPAN-2) levels may be useful in estimating the real malignant potential in all patients with PDAC because DUPAN-2 levels do not depend on the Lewis antigen phenotype.^{1,2}

FUTURE

The combined use of CA19-9 and DUPAN-2 may define a novel criterion of borderline resectability.

FUNDING Open Access funding provided by Hiroshima University. This study received no financial support.

DISCLOSURE The authors declare no conflicts of interest associated with this manuscript.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

REFERENCES

1. Shimizu Y, Sugiura T, Ashida R, et al. Prognostic role of preoperative duke pancreatic monoclonal antigen type 2 levels in patients with pancreatic cancer. *Ann Surg Oncol.* 2023;30:5792–800.
2. Sumiyoshi T, Uemura K, Shintakuya R, et al. Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma. *Ann Surg Oncol.* 2024. <https://doi.org/10.1245/s10434-024-15221-z>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article refers to: Sumiyoshi T, Uemura K, Shintakuya R, et al. Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma. *Ann Surg Oncol.* (2024). <https://doi.org/10.1245/s10434-024-15221-z>.

© The Author(s) 2024

First Received: 20 March 2024

Accepted: 22 March 2024

K. Uemura, MD
e-mail: umk@hiroshima-u.ac.jp

Published online: 13 May 2024